Health
Gilead to develop second-generation protease inhibitor
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Gilead to develop second-generation protease inhibitor
Gilead to develop second-generation protease inhibitor
Gilead Sciences filed an investigational new drug application Tuesday with the Food and Drug Administration to develop GS 9005, a once-daily protease inhibitor with a drug-resistance profile significantly different from those of existing protease inhibitors, The Wall Street Journal reports. Because of the drug's unique resistance profile, it could be effective for patients who've developed resistance to all other protease medications, company officials say. Gilead plans to begin early human tests later this year.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!